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Abstract 
Thymidine monophosphate kinase (TMPK) of Mycobacterium tuberculosis (TMPKmt) 
represents an attractive target for blocking the bacterial DNA synthesis. In an attempt to find 
high-affinity inhibitors of TMPKmt, a cavity in the enzyme at the 3’-position was explored 
via the introduction of various substituents at the 3’-position of the thymidine monophosphate 
(dTMP) scaffold. Various 3’-C-branched chain substituted nucleotides in the 2’-deoxyribo (3-
6) and ribo series (7, 8) were synthesized from one key intermediate (23). 2’-Deoxy analogues 
proved to be potent inhibitors of TMPKmt: 3’-CH2NH2 (4), 3’-CH2N3 (3) and 3’-CH2F (5) 
nucleotides exhibit the highest affinities within this series with Ki values of 10.5, 12 and 15 
M, respectively. These results show that TMPKmt tolerates the introduction of sterically 
demanding substituents at the 3’-position. Ribo analogues experience a significant affinity 
decrease, which is probably due to steric hindrance of Tyr103 in close vicinity of the 2’-
position. Although the 5’-O-phosphorylated compounds have somewhat higher affinities for 
the enzyme, the parent nucleosides generally exhibit affinities for TMPKmt in the same order 
of magnitude and display a superior selectivity profile versus human TMPK. This series of 
inhibitors holds promise for the development of a new class of anti-tuberculosis agents. 
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Introduction 
Mycobacterium tuberculosis is responsible for at least 2 million deaths per year worldwide 
and 30 million people are at risk of dying from tuberculosis (TB) in the next 10 years.1 Due to 
demographic factors, socio-economic trends, neglected tuberculosis control in many countries 
and HIV-infection, this epidemic has been able to adopt such proportions. Efforts to stop this 
frightening trend are hampered by the lack of financial resources in developing countries, the 
appearance of multi-drug resistant strains of M. tuberculosis and bad therapy compliance. As 
a current strategy in the battle against TB, Directly Observed Treatment Short-course (DOTS) 
is preferred. In DOTS, TB patients are subjected to standardized treatment regimens 
(generally consisting of combinations of the most powerful anti-TB drugs), which last 6-8 
months under direct observation of drug intake. As a consequence, the duration of illness, the 
risk of death and the appearance of resistant strains are reduced. For those that are or will be 
infected with the multi-drug-resistant bacteria or that develop resistance after a previous drug 
treatment (50-80% of previously treated cases), however, more effective drugs acting on 
novel targets are eagerly awaited.2 
Thymidine monophosphate kinase (TMPK) catalyzes the conversion of dTMP to dTDP. This 
enzyme is ubiquitous in all living organisms. It lies at the junction of the de novo and salvage 
pathways for thymidine triphosphate (dTTP) synthesis. These enzymes are well characterized, 
both at biochemical3 and structural4 levels. Li de la Sierra et al. recently determined the 
structure of M. tuberculosis TMPK (TMPKmt) using X-ray diffraction.5 Because its crucial 
role in thymidine metabolism and in view of its low (22%) sequence identity with the human 
isozyme (TMPKh), it represents an attractive target for blocking mycobacterial DNA 
synthesis. The main interactions between dTMP and the enzyme are depicted in Figure 1. The 
most important catalytic regions are:  
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- the P-loop (amino acid residues 617), which binds and positions the - and -
phosphoryl groups of the phosphate donor (ATP); it is unique among all known 
TMPK sequences in that it does not have an arginine at the position where it is found 
in the yeast and human enzymes; instead, it possesses a distant arginine residue four 
amino acids further; 
- the DRY/H-motif (residues 9496), which acts as a clip that favorably orients the 
phosphate donor and acceptor; 
- the LID-region (residues 144154) that leans over the phosphoryl donor, when dTMP 
binds the enzyme; it is very similar to E. coli TMPK having three arginines. 
Moreover, 3’-azido-3’-deoxythymidine monophosphate (AZTMP) was identified as a 
competitive inhibitor of TMPKmt with a Ki of 10 M.3d TMPKmt represents the first reported 
TMPK that does not phosphorylate AZTMP, a feature that could be exploited in the search for 
other selective inhibitors of TMPKmt. Lavie et al.4a postulated that, in yeast TMPK, the azido 
group interacts via its terminal nitrogen with the side-chain carboxyl of Asp9, resulting in a P-
loop displacement. Thus, Arg15 binds ATP less efficiently, slowing down catalysis. A similar 
mechanism may account for the lack of phosphorylation of AZTMP by TMPKmt. Li de la 
Sierra et al.5 suggested that the azido group carries the magnesium ion into the active site of 
TMPKmt (responsible for positioning one oxygen of the phosphate and Asp9), thereby 
abolishing catalysis. Despite the uncertainty of the mechanism, it should be interesting to 
explore changes at position 3’of the dTMP-scaffold for finding more potent inhibitors of 
TMPKmt. The X-ray structure of TMPK complexed with dTMP reveals that relatively bulky 
substituents at the 3’-position could be accommodated.5 Therefore, we decided to synthesize a 
series of 3’-C-branched-chain nucleotides, namely the 3’-C-azidomethyl, 3’-C-aminomethyl, 
3’-C-fluoromethyl, and 3’-C-hydroxymethyl derivatives of dTMP (3-6). To delineate the most 
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appropriate length of the spacer between the 3’-carbon and the introduced functionality, also 
3’-deoxy-3’-hydroxyethylthymidine (15) was investigated for its affinity for TMPKmt. 
We have already reported that a ribo analogue exhibits a higher affinity for TMPKmt than its 
corresponding 2’-deoxy analogue, i.e. the ribo analogue of 3’-amino-3’-deoxy-5’-O-
phosphorylthymidine (2) with a Ki of 27 M versus 235 M for 1.6 In order to gain detailed 
insight in the postulated steric hindrance caused by Tyr103 at the 2’-position, the ribo 
analogues of the azido and amino compounds were also synthesized (7-8). The non-
phosphorylated analogues 9-14 of the above-mentioned compounds were included in this 
report as well. 
 7
Results and Discussion  
Chemistry  
Although an efficient synthetic route for the synthesis of 3'-C-branched-chain 2’,3'-deoxy 
substituted thymidine has been established,7 we developed a route that gives access to both 2’-
deoxy and ribo analogues and allows easier conversion to the corresponding monophosphates. 
The synthesis of the parent 3’-C-branched-chain substituted nucleosides 9-14 was described 
by Lin et al.8 In this procedure, all 3’-C-modifications are introduced on the sugar moiety 
before coupling with thymine. In our approach, the 3’-C-modifications are effected following 
sugar-base coupling, which allows synthesizing all derivatives from a unique key 
intermediate. This approach requires a judicious choice of 5’- and 6’-O-protective groups, 
which must be stable under various reaction conditions and be chemoselectively removed to 
permit conversion of the key compound to the 3’-hydroxymethylnucleotide, on one hand and 
to the 3’-azidomethyl-, 3’-aminomethyl- and 3’-fluoromethyl-derivatives, on the other hand. 
First, we chose to combine 5-O-(tert-butyldimethyl)silyl and a 6-O-benzyl protecting groups 
(Scheme 1). However, introduction of the 6-O-protective group in 16 (prepared in 3 steps 
from 1,2-O-isopropylidene--D-xylofuranose8) using BnCl and NaH in DMF9 was 
cumbersome. The 5-O-(tert-buthyldimethyl)silyl group was cleaved thereby furnishing a 
mixture of 3-deoxy-3-(benzyloxymethyl)-1,2-O-isopropylidene--D-ribofuranose (17) (17%) 
and 5-O-benzyl-3-deoxy-3-(hydroxymethyl)-1,2-O-isopropylidene--D-ribofuranose (68%) 
(18) resulting from silyl ether cleavage and/or migration under basic conditions.10 Therefore, 
we decided to take the 5-O-p-anisyl protecting group instead of the 5-O-(tert-
butyldimethyl)silyl, as migration during introduction of the benzyl would be obviated under 
the given reaction conditions (Scheme 2). Unfortunately, attempts to selectively protect the 
primary hydroxyl of 1,2-O-isopropylidene--D-xylofuranose (19) with p-methoxyphenol 
under Mitsunobu conditions11 did not afford the desired 5’-O-protected derivative. Instead, 
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3,5-anhydro-1,2-O-isopropylidene--D-xylofuranose12 (20) was formed via intramolecular 
dehydration. 
To circumvent this problem, we protected the 5-hydroxyl as a benzyl ether and the 6-hydroxyl 
with a p-anisyl group (Scheme 3). 5-O-Benzyl-3-deoxy-3-(hydroxymethyl)-1,2-O-
isopropylidene--D-ribofuranose (18) was prepared using the method of Tino et al.12 The 3-
hydroxymethyl group was protected as a p-anisyl ether under Mitsunobu conditions,11 
affording the fully protected sugar 21. Acidic cleavage of the 1,2-O-isopropylidene group, 
followed by acetylation, provided 22. Vorbrüggen-type coupling13 of this acetylated sugar 
with silylated thymine, followed by alkaline removal of the 2’-O-acetyl protecting group 
yielded 23 (78% in 2 steps), a convenient key intermediate for further derivatization. Removal 
of the 2’-hydroxyl function was performed by reduction of its phenoxythiocarbonate ester 
with AIBN and nBu3SnH affording 24 (40% yield from 18). Selective deprotection of the 5’-
O-benzyl group of 24 by catalytic hydrogenolysis, followed by 5’-O-phosphorylation and 
removal of the p-anisyl group, gave the desired 2’,3’-dideoxy-3’-C-hydroxymethylthymidine-
5’-O-monophosphate (6) (Scheme 4). To obtain the corresponding free nucleoside 12, 25 was 
treated with ceric ammonium nitrate. Besides the removal of the 6’-O-anisyl group, oxidation 
of the 5-methyl group occurred during work-up of the aqueous layer (possibly by residual 
ceric ammonium nitrate) thereby leading to the undesired 5-hydroxymethylthymine analogue 
27. The 5-hydroxymethyl was identified by COSY (an extra hydroxymethyl was present that 
did not show COSY contacts with any other proton) and gHMBC experiments (3J contact 
between 5-CH2OH and H-6 and between 5-CH2OH and C-4 and C-6; 2J contact between 5-
CH2OH and C-5). Consequently, we interchanged the deprotection steps c and a described in 
Scheme 4 and obtained 12 via 28 (68% yield from 24).  
Compound 28 also served as precursor for the synthesis of the 3’-CH2N3, 3’-CH2NH2 and 3’-
CH2F derivatives. Fluorination of 28 with (diethylamino)sulfur trifluoride (DAST), followed 
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by reductive debenzylation, afforded the desired 2’,3’-dideoxy-3’-fluoromethylnucleoside 11. 
Phosphorylation of the 5’-hydroxyl group led to the corresponding nucleotide 5 (Scheme 4).  
Mesylation of 28 followed by treatment with NaN3 afforded azide 30 in 79% yield (2 steps) 
(Scheme 5). Debenzylation (BCl3 in CH2Cl2), followed by 5’-phosphorylation, furnished 3’-
C-azidomethyl nucleotide 3. Reduction of the azido group in 3 with Ph3P and NH4OH in 
pyridine led to the 3’-CH2NH2 derivative 4. Likewise 9 was converted to 10. 
The synthesis of the 3’-C-aminomethyl and 3’-C-azidomethyl ribo analogues from 23 was 
performed in a similar way as for the 2’-deoxy analogues. After selective removal of the p-
anisyl group of 23, the 6’-azido moiety was introduced via mesylation and treatment with 
NaN3 to yield nucleoside 13 after deprotection. Phosphorylation of 13 led to analogue 7 and 
subsequent reduction of the 6’-azido group afforded analogue 8. Similarly, reduction of the 
azido group of 13 afforded 14.  
Compound 15 was obtained according to reported procedures with slight modifications 
(Scheme 6). An allyl group was introduced at the 3'-position of 5'-silylated thymidine by a 
free-radical coupling described by C.K. Chu14 to give nucleoside 33. Aldehyde 34 was 
obtained from 33 by a two-step one-pot procedure involving cis-hydroxylation with osmium 
tetraoxide in the presence of 4-methylmorpholine N-oxide and sodium periodate cleavage of 
the diol.15 Reduction of 34 with sodium borohydride in aqueous ethanol, followed by 5'-
desilylation of the alcohol 35, afforded the free nucleoside 15 in 24% yield from 33.16 
Binding Assay 
All compounds were tested as described in the experimental section17 and are presented in 
Table 1. Clearly, 2’-deoxy nucleotides 3-6 are potent inhibitors of TMPKmt. The 3’-CH2NH2 
nucleotide 4, its 3’-CH2N3 precursor 3 and the 3’-CH2F nucleotide 5 exhibit the highest 
affinities within this series with Ki values of 10.5 M, 12 M and 15 M, respectively. A 
modeling experiment (in GOLD) showed that 4 adopts a 2’-exo-3’-endo conformation 
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(dTMP, in contrast, is in the crystal in the 2’-endo-3’-exo conformation). Consequently, the 
amino group occupies the same space as the 3’-hydroxylgroup of dTMP, hence it is in an 
appropriate position to interact with Asp9 (Figure 2).  
These results indicate that TMPKmt can accommodate sterically more demanding 
substituents at the 3’-position. Since 5 binds the enzyme as efficiently as 3 and 4, ionic 
interaction with Asp9 seems not a prerequisite for effective affinity. Interestingly, deletion of 
the phosphate moiety typically results in a modest (at most 6-fold) affinity loss, while this 
effect is negligible in the case of the 3’-CH2OH substituent. The largest discrepancy between 
the Ki values of the free and phosphorylated forms is found for the 3’-CH2NH2 couple. The 
positively charged ammonium ion may well interact with the negatively charged phosphate 
moiety, thereby forcing the nucleotide in a favorable conformation for interaction with 
TMPKmt. In the absence of the phosphoryl group, this conformation is no longer preferred 
and the conformational mobility of the 3’-CH2NH2 may account for the loss of affinity. 
Because nucleotide 2 has a much higher affinity than the corresponding 2’-deoxyribo 
analogue 1, compound 8 was expected to be active. However, introduction of a methylene 
spacer between the NH2-group and C-3’ of 2, leads to 8 with a 30-fold lower affinity than the 
deoxyribo analogue 4. The affinities of the other ribo analogues were weak, the smallest 
decrease (6-fold) in affinity upon introduction of the 2’-hydroxyl being found for 14. 
Apparently, the presence of Tyr103 close to the 2’-position impedes favorable binding 
characteristics of these ribo analogues. Thus, compound 2 is the only ribo analogue with a 
higher affinity than its deoxy counterpart. 
In order to probe the influence of the arm length at position 3’, 15 was synthesized. Its Ki 
value was 5.8 and 3.8 times higher than that of dT (n= 0) and 12 (n = 1), respectively.  
The selectivity of all target compounds for TMPKmt versus TMPKh was evaluated. All are 
inhibitors of TMPKh except the 3'-hydroxymethylnucleotide 6, which behaves as a weak 
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substrate. Most nucleotides (3, 5, 6 and 8) show affinities for TMPKh that lie in the same 
order of magnitude as those for TMPKmt. The non-phosphorylated 3'-C-branched-chain 
nucleosides 9, 11 and 12, on the other hand exhibit very low affinities for TMPKh, which 
results in selectivity indexes between 10 and 26. Somehow a 3'-CH2N3 functionality combined 
with a 2'-hydroxyl seems to introduce a TMPKmt versus TMPKh selectivity in these 3'-C-
branched-chain analogues, whereas an opposite tendency is observed upon reduction of the 3'-
CH2N3 group. To conclude, nucleosides 9, 11 and 12 emerge as the inhibitors that combine a 
low Ki value with a favourable SI ratio and are therefore put forward as promising leads for 
further research. 
 
Conclusions 
In the search for more potent drugs to treat tuberculosis, the discovery of new leads with a 
novel mechanism of action is of utmost importance. From this point of view, TMPKmt 
represents an attractive potential target for the rational design of inhibitors, mainly because of 
its crucial positioning in the metabolic activation of thymidine and because of the different 
structures between the enzymes of the bacterium and the host.  
This work describes the synthesis of a number of 3’-C-branched chain-substituted substrate 
analogues of dTMP in the ribo and 2’-deoxyribo series. 
Several 3'-deoxy 3'-C-branched chain-substituted dTMP analogues (3-5) emerged as 
promising leads for the design of novel antituberculosis agents. These molecules have a high 
diversity at the 3’-substitution site: the fluorine atom in 5 is sterically much smaller than an 
azido group in 3, while the amino group of 4 is positively charged. The Ki values of these 
compounds for TMPKmt are very similar. This suggests that they bind in a different way 
involving (most probably) Asp9 and Tyr103 and the Mg2+ ion present near the 5’-O-
phosphate group. As these nucleosides have a 3’-C substituent, they lack the gauche effect 
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that might stabilize 2’-deoxynucleosides in the South type conformation. In a cooperative 
manner, a voluminous 3’-substituent should preferably occupy a pseudoequatorial position, 
which is achieved in the North type conformation. On the other hand, the steric interactions 
between the 3'-H and the thymine base should theoretically drive their pseudorotational 
equilibria to the South type sugar conformation. This conformational mobility, together with 
the flexibility of the amino acid side chain in the active site, renders prediction of binding 
affinities of nucleoside analogues difficult. 
Importantly, it should be noted that introduction of a hydroxyl group at the 2’-position leads 
to an increase in affinity for the 3’-amino analogues 1 and 2, which is a remarkable feature for 
an enzyme that metabolizes only 2’-deoxynucleotides. However, protonation of the 3’-amino 
group may affect the conformation of the nucleotide, as well as its interaction with the 
enzyme. The most important observation refers to the small differences in binding affinities of 
the 5’-O-phosphorylated and non-phosphorylated analogues, as adequately shown in the very 
similar activities of 6 and 12. This result facilitates further elaboration, as it is generally 
accepted that 5’-O-phosphorylated nucleosides are hardly taken up by cells. Originally, our 
objective was to synthesize modified nucleoside 5’-O-phosphates that are not prone to further 
phosphorylation in order to avoid cell toxicity. However, we confirmed that non-
phosphorylated analogues are as active as their phosphorylated analogues.6b In addition 
affinity tests on TMPKh indicated that nucleosides have a significantly better selectivity 
profile vis à vis TMPKh. Therefore, we will pursue in this area. Further research will be 
directed to (i) exploration of other 3’-substituents of 2’,3’-dideoxythymidine with increased 
affinities and (ii) investigation of the most appropriate 5’-substituent devoid of 
phosphorylation capacity and, thus, associated to a low risk of toxicity. 
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Experimental Section 
(1) Spectrophotometric binding assay. 
The in vitro tests were done on recombinant enzymes overexpressed in E. coli: TMPKmt3d  
and TMPKh (will be described elsewhere by Pochet et al.). TMPKmt and TMPKh activities 
were determined using the coupled spectrophotometric assay described by Blondin et al.17 at 
334 nm in an Eppendorf ECOM 6122 photometer. The reaction medium (0.5 ml final volume) 
contained 50 mM Tris-HCl pH 7.4, 50 mM KCl, 2 mM MgCl2, 0.2 mM NADH, 1 mM 
phosphoenol pyruvate and 2 units each of lactate dehydrogenase, pyruvate kinase and 
nucleoside diphosphate kinase. The concentrations of ATP and dTMP were kept constant at 
0.5 mM and 0.05 mM respectively, whereas the concentrations of analogues varied between 
0.01 and 4 mM. 
(2) Modeling 
The X-ray structure of TMPKmt published by de la Sierra et al.5 (pdb entry 1G3U) was used 
in all docking experiments. Water molecules and sulphate counter ions were removed. The 
Mg2+ was considered as being part of the enzyme. Explicit hydrogen atoms were added to the 
enzyme and inhibitor structures using Reduce.18 PDB files were then converted to mol2 files 
using Babel.19 The position of atom C1' in the dTMP ligand in the pdb file 1G3U was used as 
the center of a 20 Å docking sphere. Default settings were used in Gold for all dockings.20,21 
The structures in the top 25 of the docking scores were retained for visual inspection and 
analysis. Figures 1 and 2 were generated using Molscript.22 
(3) Synthesis. General. NMR spectra were obtained with a Varian Mercury 300 or a Unity 
500 spectrometer. Chemical shifts are given in ppm () relative to residual solvent peak in the 
case of DMSO-d6 (2.5 ppm). All signals assigned to amino and hydroxyl groups were 
exchangeable with D2O. Mass spectra and exact mass measurements were performed on a 
quadrupole/orthogonal-acceleration time-of-flight (Q/oaTOF) tandem mass spectrometer 
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(qTof 2, Micromass, Manchester, UK) equipped with a standard electrospray ionisation (ESI) 
interface. Samples were infused in a 2-propanol:water (1:1) mixture at 3 µL/min. The final 
nucleoside 5’-O-monophosphates were ultimately purified using a Gilson HPLC system with 
a Gilson 322 pump, a UV/VIS-156 detector on a C18 column (10 µM; Altech; Altima; 250  
22 mm). The final nucleosides were purified by HPLC on a Perkin Elmer system with a 
diode-array ultraviolet absorption detector. A Kromasil reverse phase column (C18, 250 x 4.6 
mm) was used with a linear gradient of acetonitrile (A) in 10 mM triethylammonium acetate 
buffer at pH 7.5 (B) over 20 min at a flow rate of 5.5 ml/min. The purity of all target 
compounds was assessed by HPLC using either a reverse phase column (Kromasil C18) with 
a linear gradient of A in B at a flow rate of 1 ml/min over 20 min (method A) or an anion-
exchange column (Mono Q HR5/5) with a linear gradient of 1 M triethylammonium 
bicarbonate buffer at pH 7.8 in water (method B). 
Precoated Merck silica gel F254 plates were used for TLC and spots were examined under UV 
light at 254 nm and revealed by sulfuric acid-anisaldehyde spray or phosphomolybdic acid 
(0.5% in EtOH) solution. Column chromatography was performed on Uetikon silica (0.2-0.06 
mm).  
Anhydrous solvents were obtained as follows: THF was distilled from sodium/benzophenone; 
pyridine was refluxed overnight over potassium hydroxide and distilled; dichloromethane, 
dichloroethane and toluene were stored over calcium hydride, refluxed, and distilled; DMF 
was stored over Linde 4 Å molecular sieves, followed by distillation under reduced pressure.  
3-[(p-Anisyloxy)methyl]-5-O-benzyl-3-deoxy-1,2-O-(isopropylidene)--D-ribofuranose 
(21). To a solution of 1812 (612 mg, 2.08 mmol), Ph3P (708 mg, 2.7 mmol) and p-
methoxyphenol (775 mg, 6.24 mmol) in THF (6 mL) was added dropwise diethyl 
azodicarboxylate (0.42 mL, 2.7 mmol). The reaction mixture was heated to 80 °C and stirred 
for 1.5 h. The mixture was diluted with ether (150 mL) and the organic layer was washed with 
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water (150 mL), dried over MgSO4 and evaporated. The resulting residue was purified by 
column chromatography (pentaneEtOAc, 9:1) yielding 21 (724 mg, 87%) as a foam. 1H 
NMR (300 MHz, CDCl3):  1.28 and 1.43 (6 H, 2s, CMe2), 2.38 (1H, m, H-3), 3.63 (1H, dd, 
H-5B), 3.78 (3H, s, OCH3), 3.83 (1H, dd, J5A, 5B = 10.8 Hz, H-5A), 3.97 and 4.25 (2H, 2dd, 
6-H) , 4.15 (1H, m, H-4), 4.54 and 4.66 (2H, 2d, CH2Ph), 4.79 (1H, app t, H-2,) 5.89 (1H, d, J 
= 3.7 Hz, H-1), 6.80 (4H, m, 4-MeOPh), 7.34 (5H, m, CH2Ph); HRMS (ESI-MS) for 
C23H28O6Na M + Na+: found, 423.1813; calcd, 423.1783.  
1,2-Di-O-Acetyl-3-[(p-anisyloxy)methyl]-5-O-benzyl-3-deoxy--D-ribofuranose (22). A 
solution of 21 (7.812 g, 19.51 mmol) in 75% HOAc (200 mL) was stirred at 80 °C for 8 h. 
The reaction mixture was evaporated to give crude 5-O-benzyl-3-deoxy-3-[(p-
anisyloxy)methyl]--D-ribofuranose as a syrup. The obtained residue was dissolved in 
pyridine (150 mL) and acetic anhydride (23 mL, 246 mmol) was added. The solution was 
stirred at room temperature for 3 h. The solvent was removed under vacuum and the resulting 
residue was purified by column chromatography (pentaneEtOAc, 8:2) to yield 22 (8.039 g, 
93%) as a foam. 1H NMR (300 MHz, CDCl3):  1.96 and 2.05 (6H, 2s, 2 COCH3), 2.96 (1H, 
m, H-3), 3.57–3.73 and 4.00–4.14 (4H, 2m, H-5 and H-6), 3.78 (3H, s, OCH3), 4.33 (1H, m, 
H-4), 4.59 (2H, app d, CH2Ph), 5.40 (1H, m, H-2), 6.12 and 6.46 (1H, s and d, H-1 and H-1 
), 6.81 (4H, m, 4-MeOPh), 7.34 (5H, m, CH2Ph); HRMS (ESI-MS) for C24H28O8Na M + 
Na+: found, 467.1707; calcd, 467.1682. 
1-3-[(p-Anisyloxy)methyl]-5-O-benzyl-3-deoxy--D-ribofuranosylthymine (23). 
Thymine (225 mg, 1.78 mmol) was suspended in hexamethyldisilazane (20 mL, 95 mmol) 
containing trimethylsilylchloride (0.16 mL, 1.26 mmol) and pyridine (1.6 mL). The mixture 
was heated at reflux overnight. The reaction mixture was evaporated and coevaporated with 
toluene. The resulting residue and 22 (720 mg, 1.62 mmol) were dissolved in dry 1,2-
dichloroethane (12 ml) and trimethylsilyl triflate (0.34 ml, 1.88 mmol) was added dropwise. 
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The clear solution was stirred 5 h at room temperature. The reaction mixture was diluted with 
CH2Cl2 (200 mL) and washed with saturated aqueous NaHCO3. The organic layer was dried 
over MgSO4 and evaporated. The resulting crude 1-[2-O-acetyl-3-[(p-anisyloxy)methyl]-5-O-
benzyl-3-deoxy--D-ribofuranosyl]thymine was treated with a 7N methanolic ammonia 
solution (19 mL) at room temperature for 15 h. Evaporation yielded a residue which was 
purified by column chromatography (CH2Cl2MeOH, 98:2) to afford 23 (592 mg, 78%) as a 
white foam. 1H NMR (300 MHz, DMSO-d6):  1.39 (3 H, s, 5-CH3), 2.68 (1H, m, H-3’), 3.69 
(3H, s, OCH3), 3.73 (1H, app dd, H-2’), 3.95 (2H, m, H-5’), 4.174.31 (3H, m, H-4’ and H-
6’), 4.59 (2H, 2 app d, CH2Ph), 5.72 (1H, app s, H-1’), 5.88 (1H, d, 2’-OH), 6.85 (4H, s, 4-
MeOPh), 7.33 (5H, m, CH2Ph), 7.74 (1H, d, J6, 5-CH3 = 1.0, H-6); HRMS (ESI-MS) for 
C25H28N2O7Na M + Na+: found, 491.1820; calcd, 491.1794. 
1-3-[(p-Anisyloxy)methyl]-5-O-benzyl-2,3-dideoxy--D-erythro-pentofuranosylthymine 
(24). To an ice-cold solution of 23 (6.55 g, 14.0 mmol) and DMAP (3.42 g, 28.0 mmol) in 
CH3CN (290 mL) was gradually added phenyl chlorothionocarbonate (2.6 mL, 18.8 mmol). 
The mixture was stirred at 0 °C for 1.5 h. The solvent was removed in vacuo, and the residue 
was dissolved in EtOAc (500 mL). The solution was washed with water (2 x 500 mL), dried 
over anhydrous MgSO4, filtered, and evaporated in vacuo to give 1-[3-[(p-anisyloxy)methyl]-
5-O-benzyl-3-deoxy-2-O-(phenoxycarbonothioyl)--D-ribofuranosyl]thymine as a syrup. The 
syrup was dissolved in toluene (290 mL) to which 2,2’-azobis(2-methyl-propionitrile) (AIBN, 
5.89 g, 35.87 mmol) and tri-n-butyltinhydride (8.00 g, 27.5 mmol) were added at 50-60 °C 
under N2. The reaction mixture was stirred at 95-100 °C for 1 h. The solvent was removed in 
vacuo and the residue was purified by column chromatography (pentaneEtOAc, 2:1) to yield 
24 (3.98 g, 63%) as a foam. 1H NMR (300 MHz, DMSO-d6):  1.52 (3 H, s, 5-CH3), 2.24-
2.29 (2H, m, H-2’), 2.80 (1H, m, H-3’), 3.69 (3 H, s, OCH3), 3.71 (1H, m, H-5’B), 3.87 (1H, 
dd, J5’A, 5’B = 10.9 Hz, H-5’A), 3.944.06 (3H, m, H-4’ and H-6’), 4.53 and 4.57 (2H, 2d, 
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CH2Ph), 6.1 (1H, dd, J = 7.0 Hz, H-1’), 6.87 (4H, s, 4-MeOPh), 7.287.36 (5H, m, CH2Ph), 
7.67 (1H, br s, H-6); MS (ESI) m/z (%) 475.2 (M + Na+, 100), 453.2 (M + H+, 47). 
1-3-[(p-Anisyloxy)methyl]-2,3-dideoxy--D-erythro-pentofuranosylthymine (25). A 
solution of 24 (730 mg, 1.61 mmol) in MeOH (40 ml) was hydrogenated at atmospheric 
pressure for 5h in the presence of 10% Pd/C (390 mg). The catalyst was removed by filtration 
through celite and the filtrate was concentrated in vacuo. The residue was purified by column 
chromatography (CH2Cl2MeOH, 98:2) to give 496 mg (85%) of the debenzylated 
intermediate 25 as a white foam. 1H NMR (300 MHz, DMSO-d6):  1.78 (3 H, s, 5-CH3), 
2.132.28 (2H, m, H-2’), 2.70 (1H, m, H-3’), 3.64 (1H, m, H-5’B), 3.69 (3H, s, OCH3) 3.78 
(1H, m, H-5’A), 3.88 (1H, m, H-4’), 3.96 (2H, d, H-6’), 5.13 (1H, t, J = 5.3 Hz, 5’-OH), 6.09 
(1H, dd, H-1’), 6.87 (4H, m, 4-MeOPh), 7.88 (1H, d, J = 1.2 Hz, H-6); HRMS (ESI-MS) for 
C18H22N2O6Na M + Na+: found, 385.1413; calcd, 385.1375.  
1-(2,3-Dideoxy-3-hydroxymethyl--D-erythro-pentofuranosyl)-5-hydroxymethylthymine 
(27). To a solution of 25 (124 mg, 0.34 mmol) in CH3CNH2O (4:1) (5.5 mL) was added 
ceric ammonium nitrate (940 mg, 1.70 mmol). After 5 min the mixture was diluted with water 
(20 mL), washed with CHCl3 (20 mL) and the aqueous layer was evaporated. The residue was 
purified by column chromatography (CH2Cl2MeOH, 95:590:10) to give 27 (36 mg, 39%) 
as a foam. 1H NMR (500 MHz, DMSO-d6):  2.17 (ddd, J1’, 2’ = 4.6 Hz, H-2’), 2.00 (1H, dt, 
J2’, 2’’ = 13.7 Hz, J1’, 2’’ = 7.2 Hz, H-2’’), 2.31 (1H, m, H-3’), 3.44 (2H, m, H-6’), 3.67 and 3.55 
(2H, 2m, H-5’), 3.78 (1H, dt, H-4’), 4.13 (2H, s, 5-CH2), 4.76 (1H, t, 6’-OH), 4.86 (1H, t, 5-
CH2OH), 4.94 (1H, t, 5’-CH2OH), 6.01 (1H, dd, J1’, 2’ = 4.4 and J1’, 2’’ = 6.9 Hz, H-1’), 7.81 
(1H, s, H-6), 11.24 (1H, s, H-3); 13C NMR (125 MHz, DMSO-d6):  35.04 (C-2’), 40.82 (C-
3’), 56.07 (5-CH2), 61.59 (C-6’), 62.62 (C-5’), 83.47 (C-4’), 84.26 (C-1’), 113.7 (C-5’), 
137.01 (C-6), 150.33 (C-2), 162.98 (C-4); MS (ESI) m/z (%) 295.1 (M + Na+, 70). 
General procedure for the selective phosphorylation of the 5’-hydroxylgroup. 
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To a cooled (0 °C) solution of the nucleoside (0.42 mmol) in trimethyl phosphate (10 
mL/mmol), POCl3 (6.5 eq) was added dropwise and the mixture was stirred for 5 h at 0 °C 
and for 30 min at room temperature, after which it was poured into crushed ice-water (10 
mL), neutralized with concentrated NH4OH and evaporated to dryness. The resulting residue 
was purified by column chromatography (iPrOH NH4OHH2O, 77.5:15:2.560:30:5). 
Further purification of the white powder by HPLC (C-18, CH3CNMeOH0.05% HCOOH in 
H2O 45:45:10, 3 mL/min) and lyophilisation of the appropriate fractions, provided the 
nucleotide as a white powder. 
1-3-[(p-Anisyloxy)methyl]-2,3-dideoxy-5-O-phosphoryl-D-erythro-
pentofuranosylthymine (26). 25 was phosphorylated as described in the general procedure 
and nucleotide 26 isolated in 52% yield. 1H NMR (300 MHz, D2O):  1.94 (3 H, s, 5-CH3), 
2.282.44 (2H, m, H-2’), 2.86 (1H, m, H-3’), 3.81 (3H, s, OCH3), 4.054.26 (5H, m, H-6’, H-
4’ and H-5’), 6.22 (1H, dd, J = 5.2 and 6.6 Hz, H-1’), 6.98 (4H, m, 4-MeOPh), 7.80 (1H, d, J 
= 0.9 Hz, H-6); 13C NMR (125 MHz, D2O):  14.26 (5-CH3), 37.21 (C-2’), 40.77 (C-3’), 
58.51 (OCH3), 68.36 (C-5’, 2JC, P= 19.6 Hz), 72.19 (C-6’), 84.83 (C-4’, 3JC, P= 8.8 Hz), 88.15 
(C-1’), 113.86, 117.71 and 118.76 (C-5 and arom H), 140.13 (C-6), 154.18, 155.28, 156.10 
(C-2 and arom H), 169 (C-4); 31P NMR (500 MHz, D2O):  1.03; HRMS (ESI-MS) for 
C18H24N2O9P M + H+: found, 443.1231; calcd, 443.1219.  
1-[2,3-Dideoxy-3-(hydroxymethyl)-5-O-phosphoryl--D-erythro-pentofuranosyl]thymine 
(6). To a solution of 26 (106 mg, 0.23 mmol) in H2O (2 mL) was added ceric ammonium 
nitrate (162 mg, 0.29 mmol). After 15 min iPrOHNH4OHH2O (60:30:5) (20 mL) was 
added, the resulting suspension was filtered and the precipitate washed with water. The 
combined filtrates were evaporated under reduced pressure and the residue was purified by 
column chromatography (iPrOHNH4OHH2O, 77.5:15:2.560:30:5). The resulting white 
powder was further purified by HPLC (C-18, CH3CNMeOH0.05% HCOOH in H2O, 
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45:45:10, 3 mL/min) and the appropriate fractions were lyophilized yielding 6 (62 mg, 76%) 
as a white powder. 1H NMR (300 MHz, D2O):  1.93 (3 H, d, 5-CH3), 2.30 (2H, m, H-2’), 
2.62 (1H, m, H-3’), 3.70 (2H, d, J6’, 3’ = 6.1 Hz, H-6’), 4.01 (1H, m, H-4’), 4.14 (2H, m, H-5’), 
6.16 (1H, dd, J = 5.0 and 6.7 Hz, H-1’), 7.83 (1H, d, J = 1.2 Hz, H-6); 13C NMR (125 MHz, 
D2O):  14.28 (5-CH3), 37.10 (C-2’), 43.04 (C-3’), 64.75 (C-6’), 67.88 (C-5’), 85.21 (C-4’), 
88.01 (C-1’), 140.42 (C-6); 31P NMR (500 MHz, D2O):  1.03; HRMS (ESI-MS) for 
C11H18N2O8P M + H+: found, 337.0817; calcd, 337.0800. 
1-[5-O-Benzyl-2,3-dideoxy-3-(hydroxymethyl)--D-erythro-pentofuranosyl]thymine (28). 
To a solution of 24 (3.3 g, 7.29 mmol) in CH3CNH2O (4:1) (120 mL) was added ceric 
ammonium nitrate (19.89 g, 36.68 mmol). After 5 min the mixture was diluted with CHCl3 
(300 mL), washed with brine (200 mL) and a saturated solution of Na2S2O5 (200 mL), dried 
over MgSO4, filtered and evaporated. The residue was purified by column chromatography 
(CH2Cl2MeOH, 97:3) to give the expected product 28 (1.810 g, 72%) as a foam. 1H NMR 
(300 MHz, DMSO-d6):  1.52 (3 H, d, 5-CH3), 2.012.19 (2H, m, H-2’), 2.44 (1H, m, H-3’), 
3.46 (2H, app t, H-6’), 3.64 (1H, dd, H-5’B), 3.79 (1H, dd, J5’A, 5’B = 10.8 Hz, H-5’A), 3.95 
(1H, m, H-4’), 4.56 (2H, app s, CH2Ph), 4.82 (1H, t, 6’-CH2OH), 6.01 (1H, dd, J = 7.0 and 
4.5 Hz, H-1’), 7.36 (5H, m, CH2Ph), 7.64 (1H, d, J = 1.1 Hz, H-6); HRMS (ESI-MS) for 
C18H22N2O5Na M + Na+: found, 369.1455; calcd, 369.1426. 
1-[2,3-Dideoxy-3-(hydroxymethyl)--D-erythro-pentofuranosyl]thymine (12). 
Hydrogenation of 28 (62.0 mg, 0.179 mmol) was accomplished at atmospheric pressure of H2 
at room temperature for 45 min using 10% Pd/C (50 mg) in MeOH (5 mL). Column 
chromatography (CH2Cl2MeOH, 95:5) yielded 12 (43.4 mg, 95%) as a white foam. 1H NMR 
(300 MHz, DMSO-d6):  1.78 (3 H, d, J = 1.0 Hz, 5-CH3), 1.972.04 (2H, m, H-2’), 2.36 
(1H, m, H-3’), 3.44 (2H, app d, J6’, 3’ = 5.7 Hz, 6’-H), 3.56 (1H, dd, H-5’B) 3.69 (1H, dd, J5’A, 
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5’B = 11.9 Hz, H-5’A), 3.78 (1H, m, H-4’), 4.76 and 5.03 (2H, 2t, 5’-OH and 3’-OH), 5.98 
(1H, dd, J = 4.6 and 6.9 Hz, H-1’), 7.84 (1H, br s, H-6); HRMS (ESI-MS) for C11H16N2O5Na 
M + Na+: found, 279.0953; calcd, 279.0957. Anal. (C11H16N2O5) C, H, N. 
1-[5-O-Benzyl-2,3-dideoxy-3-(fluoromethyl)--D-erythro-pentofuranosyl]thymine (29). 
DAST (0.280 mL, 2.12 mmol) was dissolved in CH2Cl2 (5 mL) and pyridine (0.36 mL) at 0 
°C under nitrogen. Nucleoside 28 (619 mg, 1.79 mmol) was added in several portions and the 
solution was allowed to warm to room temperature. After 7 h, the solvent was removed under 
vacuum to give a syrup which was purified by column chromatography (CH2Cl2MeOH, 
99:1) to yield 29 (185 mg, 30%) as a white foam. 1H NMR (300 MHz, DMSO-d6):  1.54 (3 
H, s, 5-CH3), 2.102.23 (2H, m, H-2’), 2.692.80 (1H, m, H-3’), 3.65 (1H, dd, H-5’B), 3.80 
(1H, dd, J5’A, 5’B = 10.9 Hz, H-5’A), 4.02 (1H, m, H-4’), 4.454.61 (4H, m, H-6’ and 
CH2Ph), 6.05 (1H, dd, J = 4.7 and 7.0 Hz, H-1’), 7.35 (5H, m, CH2Ph), 7.62 (1H, d, J = 1.1 
Hz, H-6); HRMS (ESI-MS) for C18H22FN2O4 M + H+: found, 349.1586; calcd 349.1563.  
1-[2,3-Dideoxy-3-(fluoromethyl)--D-erythro-pentofuranosyl]thymine (11). A solution of 
compound 29 (185 mg, 0.531 mmol) in MeOH (8 mL) was hydrogenated at atmospheric 
pressure in the presence of Pd/C 10% (107 mg) for 5 h. The catalyst was removed by filtration 
over a celite path, the solvent evaporated in vacuo and the residue purified by column 
chromatography (CH2Cl2MeOH, 95:5) yielding 11 (134 mg, 98%) as a white foam. 1H NMR 
(300 MHz, DMSO-d6):  1.78 (3 H, s, 5-CH3), 2.062.21 (2H, m, H-2’), 2.602.71 (1H, m, 
H-3’), 3.56 (1H, dd, H-5’B), 3.71 (1H, dd, J5’A, 5’B = 12.0 Hz, H-5’A), 3.84 (1H, m, H-4’), 
4.444.57 (2H, dd, J6’, F = 47.3 Hz, H-6’), 5.14 (1H, br s, 5’-OH), 6.02 (1H, dd, J = 4.9 and 
6.7, H-1’), 7.82 (1H, s, H-6); 13C NMR (75 MHz, DMSO-d6):  62.19 (C-5’), 83.04 (C-4’, J4’, 
F = 4.5 Hz), 84.50 (C-1’), 85.64 (C-6’, J6’, F = 179 Hz), 109.64 (C-6), 136.96 (C-5), 151.06 (C-
4), 164.50 (C-2), under DMSO-signal (C-3’), 34.50 (C-2’, J2’, F = 5.3 Hz), 12.95 (5-CH3); 19F 
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NMR (300MHz, DMSO-d6):  222.73; HRMS (ESI-MS) for C11H16FN2O4 M + H+: found, 
259.1119; calcd, 259.1093. Anal. (C11H15FN2O4) C, H, N. 
1-[2,3-Dideoxy-3-(fluoromethyl)-5-O-phosphoryl--D-erythro-pentofuranosyl]thymine 
(5). Phosphorylation of 11 was performed as described in the general procedure and the title 
compound isolated in 49% yield. 1H NMR (300 MHz, D2O):  1.94 (3 H, s, 5-CH3), 
2.292.44 (2H, m, H-2’), 2.772.89 (1H, m, H-3’), 4.004.22 (2H, m, H-5’), 4.25 (1H, m, H-
4’), 4.534.70 (2H, m, H-6’), 6.16 (1H, dd, J = 5.0 and 7.0 Hz, H-1’), 7.84 (1H, d, J = 1.2 Hz, 
H-6); 13C NMR (75 MHz, D2O):  11.69 (5-CH3), 33.45 (C-2’, J2’, F = 6.0 Hz), 65.30 (C-5’), 
38.66 (C-3’, J3’, F = 19.6 Hz), 81.50 (C-4’, J4’, F = 6.7 Hz), 84.10 (C-6’, J6’, F = 165.2 Hz), 
85.43 (C-1’), 111.40 (C-6), 137.69 (C-5), 151.80 (C-4), 166.80 (C-2); 19F NMR (300 MHz, 
D2O):  224.50; 31P NMR (500 MHz, D2O):  1.12; HRMS (ESI-MS) for C11H17FN2O7P M 
+ H+: found, 339.0806; calcd, 339.0757. 
1-[3-(Azidomethyl)-5-O-benzyl-2,3-dideoxy--D-erythro-pentofuranosylthymine (30). 
Methanesulfonyl chloride (0.180 mL, 2.33 mmol) was added to a solution of compound 28 
(306 mg, 0.883 mmol) in pyridine (3 mL) at 0 °C. The reaction mixture was stirred at 0 °C 
during 1 h. Then it was diluted with CH2Cl2 (50 mL), washed with saturated aqueous 
NaHCO3 (50 mL) and dried over anhydrous MgSO4. The solvent was removed under 
diminished pressure to give the crude mesylate. The obtained residue was dissolved in DMF 
(16 mL) and treated with NaN3 (574 mg 8.83 mmol) at 95 °C for 1.5 h to complete the 
reaction. The reaction mixture was evaporated to dryness in vacuo and the residue was 
dissolved in CH2Cl2 (50 mL). The organic layer was washed with water (50 mL), dried over 
anhydrous MgSO4 and evaporated to give a sirup which was purified by column 
chromatography (CH2Cl2MeOH, 99:1) yielding 30 (260 mg, 79%) as a white foam. 1H NMR 
(300 MHz, DMSO-d6):  1.52 (3 H, d, 5-CH3), 2.50 (2H, m, H-2’), 2.60 (1H, m, H-3’), 
3.463.59 (2H, 2dd, H-6’), 3.66 (1H, dd, H-5’B), 3.83 (1H, dd, J5’A, 5’B = 10.4 Hz, H-5’A), 
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3.93 (1H, m, H-4’), 4.57 (2H, app s, CH2Ph), 6.04 (1H, app t, J = 5.9 Hz, H-1’), 7.31 (5H, m, 
CH2Ph), 7.62 (1H, br s, H-6); HRMS (ESI-MS) for C18H21N5O4Na M + Na+: found, 
394.1489; calcd, 394.1491.  
1-[3-(Azidomethyl)-2,3-dideoxy--D-erythro-pentofuranosyl]thymine (9). To a solution of 
30 (1.49 g, 4.01 mmol) in CH2Cl2 (160 mL) at –78 °C was slowly added a 1M solution of 
BCl3 in CH2Cl2 (16.1 mL, 16.1 mmol). After 15 min MeOH (5 mL) was added and the 
reaction mixture was evaporated to dryness under reduced pressure. The resulting residue was 
purified by column chromatography (CH2Cl2MeOH, 90:10) affording 9 (1.00 g, 89%) as a 
white foam. 1H NMR (300 MHz, DMSO-d6):  1.78 (3 H, d, 5-CH3), 2.13 (2H, m, H-2’), 2.51 
(1H, m, H-3’), 3.51 (2H, app d, H-6’), 3.553.61 (1H, m, H-4'), 3.693.74 (2H, m, H-5’), 
5.13 (1H, app t, 5’-OH), 6.02 (1H, dd, J = 5.0 and 6.3 Hz, H-1’), 7.82 (1H, d, J = 1.1 Hz, H-
6); 13C NMR (125 MHz, DMSO-d6):  12.96 (5-CH3), 36.36 (C-2’), 38.07 (C-3’), 52.71 (C-
6’), 61.90 (C-5’), 84.45 and 84.13 (C-1’ and C-4’), 109.56 (C-6), 136.97 (C-5), 151.05 (C-4), 
164.51 (C-2); HRMS (ESI-MS) for C11H15N5O4Na M + Na+: found, 304.1033; calcd, 
304.1021. Anal. (C11H15N5O4) C, H, N. 
1-[3-(Aminomethyl)-2,3-dideoxy--D-erythro-pentofuranosyl]thymine (10). Compound 9 
(169 mg, 0.60 mmol) and triphenylphosphine (252 mg, 0.96 mmol) were dissolved in 
pyridine (7 mL) and stirred at room temperature. After 1h, concentrated NH4OH (6 mL) was 
added and the solution was allowed to stir for an additional 2h. Pyridine was removed under 
reduced pressure, water (8 mL) was added and the unreacted triphenylphosphine and 
triphenylphosphine oxide were removed by filtration. The filtrate was extracted with toluene 
and the water layer was evaporated under reduced pressure to give a syrup. The syrup was 
purified by column chromatography (0.175 N NH3 in CH2Cl2MeOH, 80:20) to yield amine 
10 (112 mg, 73%) as a white foam. 1H NMR (300 MHz, DMSO-d6):  1.78 (3 H, s, 5-CH3), 
2.32.14 (2H, m, H-2’), 2.24 (1H, m, H-3’), 2.552.65 (2H, m, H-6’), 3.553.71 (3H, m, H-5’ 
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and H-4’), 5.95 (1H, dd, J = 3.9 and 6.9 Hz, H-1’), 7.8 (1H, d, J = 1.1 Hz, H-6); 13C NMR (75 
MHz, DMSO-d6):  12.98 (5-CH3), 43.38, 41.60 and 37.05 (C-6’, C-3’ and C-2’), 62.27 (C-
5’), 85.49 (C-4’), 85.24 (C-1’), 109.37 (C-6), 136.95 (C-5), 151.04 (C-4), 164.51 (C-2); 
HRMS (ESI-MS) for C11H18N3O4 M + H+: found, 256.1293; calcd, 256,1296. Anal. 
(C11H17N3O4) C, H, N. 
1-[3-(Azidomethyl)-2,3-dideoxy-5-O-phosphoryl--D-erythro-pentofuranosyl]thymine 
(3). 9 was phosphorylated as described in the general procedure to yield 53% of the title 
compound. 1H NMR (300 MHz, D2O):  1.91 (3 H, s, 5-CH3), 2.33 (2H, app dd, H-2’), 2.68 
(1H, m, H-3’), 3.54 (2H, app d, J6’, 3’ = 6.3 Hz, H-6’), 4.004.19 (3H, m, H-5’ and H-4’), 6.16 
(1H, app t, J = 5.8 Hz, H-1’), 7.80 (1H, d, J = 1.1 Hz, 6-H); 13C NMR (75 MHz, D2O):  
11.75 (5-CH3), 35.36 (C-2’), 37.71 (C-3’), 52.15 (C-6’), 65.13 (C-5’), 82.62 (C-4’), 85.36 (C-
1’), 111.36 (C-6), 137.71 (C-5), 151.79 (C-4), 166.79 (C-2); 31P NMR (500 MHz, D2O):  
1.14; HRMS (ESI-MS) for C11H16N5O7P M + H+: found, 362.0889; calcd, 362.0865.  
1-[3-(Aminomethyl)-2,3-dideoxy-5-O-phosphoryl--D-erythro-pentofuranosyl]thymine 
(4). Compound 3 (476 mg, 1.26 mmol) and triphenylphosphine (528 mg, 2.01 mmol) were 
dissolved in pyridine (15 mL) and stirred at room temperature. After 1h, concentrated NH4OH 
(12.6 mL) was added and the solution was allowed to stir for an additional 6.5 h. Pyridine was 
removed at reduced pressure, water (200 mL) was added and the unreacted 
triphenylphosphine and triphenylphosphine oxide were removed by filtration. The filtrate was 
extracted with toluene and the water layer was evaporated under reduced pressure to give a 
syrup. The syrup was purified by column chromatography (iPrOHNH4OHH2O, 
77.5:15:2.560:30:5). The resulting white powder was further purified by HPLC (C-18, 
CH3CNMeOH0.05% HCOOH in H2O, 45:45:10, 3 mL/min) and the fractions containing 
the title compound were lyophilized to yield 4 (306 mg, 69%) as a white powder. 1H NMR 
(300 MHz, D2O):  1.92 (3 H, s, 5-CH3), 2.322.50 (2H, m, H-2’), 2.742.82 (1H, m, H-3’), 
 24
3.123.26 (2H, 2dd, H-6’), 4.054.12 (3H, m, H-4’ and H-5’), 6.17 (1H, dd, J = 3.7 and 7.3 
Hz, H-1’), 7.78 (1H, d, J = 1.2 Hz, H-6); 13C NMR (75 MHz, D2O):  11.76 (5-CH3), 166.79 
(C-2), 151.74 (C-4), 137.70 (C-5), 111.40 (C-6), 85.29 (C-1’), 82.72 (C-4’), 63.94 (C-5’), 
40.80 (C-6’), 36.88 (C-3’), 35.95 (C-2’); 31P NMR (500 MHz, D2O):  2.82; HRMS (ESI-
MS) for C11H19N3O7PNa M + Na+: found, 336.0980; calcd, 336.0960. 
1-[5-O-Benzyl-3-deoxy-3-(hydroxymethyl)--D-ribofuranosylthymine (31). This 
compound was synthesized from 23 (346 mg, 0.74 mmol) using the procedure described for 
28 to yield 130 mg (49%) of the title compound as a foam. 1H NMR (300 MHz, DMSO-d6):  
1.42 (3 H, s, 5-CH3), 2.31 (1H, m, J3’, 6’ = 6.6 Hz, H-3’), 3.49 and 3.68 (2H, 2m, 6’-H), 3.64 
(1H, m, H-5’B), 3.98 (1H, m, J5’A, 5’B = 11.1 Hz, H-5’A), 4.13 (1H, m, H-4’), 4.19 (1H, m, 
H-2’), 4.58 (3H, m, CH2Ph and 6’-OH), 5.60 (1H, d, J = 5.0 Hz, 2’-OH), 5.67 (1H, d, J = 1.9, 
H-1’), 7.37 (5H, m, CH2Ph), 7.70 (1H, br s, 6-H); HRMS (ESI-MS) for C18H22N2O6Na M + 
Na+: found, 385.1386; calcd, 385.1375.  
1-[3-Azidomethyl-5-O-benzyl-3-deoxy--D-ribofuranosylthymine (32). This compound 
was synthesized from 31 (130 mg, 0.36 mmol) using the same procedure as described for the 
synthesis of 30 to yield 123 mg (89%, 2 steps) of the title compound as a foam. 1H NMR (300 
MHz, DMSO-d6):  1.42 (3 H, s, 5-CH3), 2.46 (1H, m, H-3’), 3.353.90 (4H, m, H-5’ and H-
6’), 4.10 (1H, m, H-4’), 4.22 (1H, m, H-2’), 4.59 (2H, s, CH2Ph), 5.67 (1H, d, J = 1.6 Hz, H-
1’), 5.93 (1H, d, J = 5.1 Hz, 2’-OH), 7.37 (CH2Ph), 7.67 (1H, br s, H-6); HRMS (ESI-MS) for 
C18H21N5O5Na M + Na+: found, 410.1504; calcd, 410.144.  
1-[3-Azidomethyl-3-deoxy--D-ribofuranosyl]thymine (13). Debenzylation of 32 (346 mg, 
0.89 mmol) was performed as described for the synthesis of 9 to yield 210 mg (79%) of the 
title compound as a foam. 1H NMR (300 MHz, DMSO-d6):  1.76 (3 H, s, 5-CH3), 2.37 (1H, 
m, H-3’), 3.353.78 4H, m, H-5’ and H-6’), 3.91 (1H, m, H-4’), 4.20 (1H, app d, H-2’), 5.24 
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(1H, br s, 5’-OH), 5.66 (1H, d, J1’, 2’ = 1.9 Hz, H-1’), 5.94 (1H, br s, 2’-OH), 7.95 (1H, br s, 
H-6). The assignment, done by a cosy-experiment, differs from that reported in ref. 8. 13C 
NMR (75 MHz, DMSO-d6):  12.95 (5-CH3), 41.35 (C-3’), 47.90 (C-6’), 61.14 (C-5’), 75.36 
(C-2’), 82.90 (C-4’), 91.26 (C-1’), 164.53 (C-2), 151.11 (C-4), 136.93 (C-5), 109.10 (C-6); 
HRMS (ESI-MS) for C11H15N5O5Na M + Na+: found, 320.0975; calcd, 320.0971. Anal. 
(C11H15N5O5) C, H, N. 
1-[3-Aminomethyl-3-deoxy--D-ribofuranosyl]thymine (14). Reduction of azide 13 (173 
mg, 0.58 mmol) was accomplished using the procedure described for the synthesis of 11 to 
yield 123 mg (73%) of amine 14 as a foam. 1H NMR (300 MHz, DMSO-d6):  1.76 (3 H, d, 
5-CH3), 2.16 (1H, m, H-3’), 2.632.89 (2H, 2dd, H-6’), 3.59 (1H, dd, H-5’B), 3.76 (1H, dd, , 
J5’A, 5’B = 12.3 Hz, H-5’A), 3.92 (1H, m, H-4’), 4.21 (1H, app d, H-2’), 5.63 (1H, d, J = 1.4 
Hz, H-1’), 7.94 (1H, d, J = 1.1 Hz, H-6); HRMS (ESI-MS) for C11H18N3O5 M + H+: found, 
272.1245; calcd, 272.1246. Anal. (C11H17N3O5) C, H, N. 
1-[3-Azidomethyl-3-deoxy-5-O-phosphoryl--D-ribofuranosyl]thymine (7). 13 was 
phosphorylated as described in the general procedure to yield 51% of nucleotide 7. 1H NMR 
(300 MHz, D2O):  1.92 (3 H, d, 5-CH3), 2.59 (1H, m, H-3’), 3.56 and 3.66 (2H, 2dd, J6’, 3’ = 
5.8 and 8.1 Hz, H-6’), 4.04 (1H, m, H-5’B), 4.26 (1H, m, H-5’A), 4.32 (1H, app d, H-4’), 4.52 
(1H, dd, H-2’), 5.86 (1H, d, J= 2.0 Hz, H-1’), 7.89 (1H, d, J = 1.0 Hz, H-6); 13C NMR (125 
MHz, D2O):  14.28 (5-CH3), 43.40 (C-3’), 49.71 (C-6’), 66.68 (C-5’, 2JC, P = 36.0 Hz), 77.95 
(C-2’), 84.52 (C-4’, 3JC, P = 8.9 Hz), 93.83 (C-1’), 113.62 (C-5), 139.84 (C-6), 154.25 (C-2), 
169.33 (C-4); 31P NMR (500 MHz, D2O):  1.27; HRMS (ESI-MS) for C11H17N5O8P M + 
H+: found, 378.0813; calcd, 378.0814. 
1-[3-Aminomethyl-3-deoxy-5-O-phosphoryl--D-ribofuranosyl]thymine (8). Azide 7 (346 
mg, 0.74 mmol) was reduced to the corresponding amine following the procedure described 
for the preparation of 4 to yield 110 mg (65%) of the amino-nucleotide 8 as a foam. 1H NMR 
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(300 MHz, D2O):  1.92 (3 H, s, 5-CH3), 2.69 (1H, m, H-3’), 3.17 and 3.38 (2H, 2dd, J = 5.2 
and 10.2 Hz, H-6’), 4.07 and 4.17 (2H, 2m, H-5’), 4.30 (1H, app d, H-4’), 4.56 (1H, dd, H-
2’), 5.84 (1H, d, J = 1.8 Hz, H-1’), 7.86 (1H, d, J = 1.1 Hz, H-6); 13C NMR (125 MHz, D2O): 
 14.30 (5-CH3), 38.26 (C-6’), 42.22 (C-3’), 65.74 (C-5’, 2JC, P = 4.9 Hz), 77.88 (C-2’), 84.43 
(C-4’, 3JC, P = 7.8 Hz), 94.17 (C-1’), 113.72 (C-5), 139.95 (C-6), 155.51 (C-2), 169.32 (C-4); 
31P NMR (500 MHz, D2O):  3.45; HRMS (ESI-MS) for C11H19N3O8P M + H+: found, 
352.0902; calcd, 352.0909. 
2',3'-Dideoxy-3'-C-(2-hydroxyethyl)thymine (15).  
To a mixture of 5'-O-tert-butyldiphenylsilyl-3'-C-allyl-2',3'-dideoxy-thymidine (33)14 (0.80 g, 
1.58 mmol) and 4-methylmorpholine N-oxide (0,26 g, 1.91 mmol) in dioxane (10 mL) was 
added an aqueous solution of OsO4 (0.09 mmol, 1% in water). After stirring 3 h at room 
temperature under light protection, the reaction mixture was complete (TLC), then sodium 
periodate (0.53 g, 2.49 mmol) was added in small portions. After completion of the reaction 
(2 h), the mixture was diluted with ethyl acetate, filtered through celite and solids washed 
with ethyl acetate. The combined filtrates were washed with saturated aqueous NaCl, dried 
and evaporated under vacuum. To the crude aldehyde 34 in ethanol/water (6/2 mL) was added 
dropwise NaBH4 (0.18 g, 4.90 mmol) in ethanol (30 mL). After 2 h at room temperature, the 
reaction was complete. The mixture was diluted in ethyl acetate and washed with water, the 
organic layer was dried and concentrated to dryness. After purification by column 
chromatography (CH2Cl2/MeOH), compound 35 (0.24 g, 0.48 mmol) was isolated in 30% 
yield from 33 as a white foam. Compound 35 (50 mg, 0.098 mmol) was treated with a 1M 
solution of TBAF in THF (0.5 mL). After stirring 1 h at room temperature, solvent was 
evaporated and the residue was purified by HPLC on a C18 reverse phase column (5-25 % 
linear gradient of acetonitrile in 10 mM TEAA) to give compound 15 (22 mg, 81%). Rt = 
8.98 min. 1H NMR (400 MHz, D2O):  1.50 (1H, m, H-6'), 1.75 (1H, m, H-6"), 1.81 (3 H, d, 
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J6, 5-CH3 = 1.1 Hz, 5-CH3), 2.15 (1H, m, H-2'), 2.25 (2H, m, H-2" and H-3’), 3.58 (2H, m, H-7' 
and H-7"), 3.70 (1H, dd, J = 8.6, J = 4.4, H-5’), 3.79 (1H, m, H-4’), 3.86 (1H, dd, J = 12.7 Hz, 
J = 2.5 Hz, H-5’’), 6.06 (1H, dd, J = 7.2 Hz, J = 2.1 Hz, H-1’), 7.71 (1H, d, J6, 5-CH3 = 1.1 Hz, 
H-6). 13C NMR (100 MHz, D2O) : 11.92 (CH3), 33.83 (C6’), 34.46 (C3’), 37.90 (C2’), 60.51 
(C7’), 61.34 (C5’), 86.96 (C1’), 85.61 (C4’), 111.19 (C5), 138.17 (C6), 152.09 (C2), 167.00 
(C4); HRMS (ESI-MS) for C12H19N2O5 M + H+: found, 271.1288; calcd, 271.1293. Anal. 
(C12H18N2O5) C, H, N. 
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Table 1. Kinetic parameters of TMPKmt and TMPKh with the 3’-deoxy-3’-C-branched-
chain-substituted nucleosides and nucleotides.  
 
O
R3
N NH
O
O
R1R2  
Compound 
code 
R1 R2 R3 
Ki (M) 
TMPKmt 
Ki (M) 
TMPKh 
SI (Ki TMPKh/ 
Ki TMPKmt 
dTMP H OH OPO32- 4.5a 5.0a 1.1a 
Thymidine H OH OH 276b n. d. n. d. 
AZTMP H N3 OPO32- 103d 12a, 4e 1.2a 
AZT H N3 OH 286b n. d. n. d. 
1 H NH2 OPO32- 2356a n. d. n. d. 
2 OH NH2 OPO32- 276a n. d. n. d. 
3 H CH2N3 OPO32- 12 32 2.7 
4 H CH2NH2 OPO32- 10.5 4.7 0.4 
5 H CH2F OPO32- 15 40 2.7 
6 H CH2OH OPO32- 29 43.5 1.5 
7 OH CH2N3 OPO32- 116 n. ib - 
8 OH CH2NH2 OPO32- 315 280 0.9 
9 H CH2N3 OH 40 1040 26 
10 H CH2NH2 OH 57 220 3.9 
11 H CH2F OH 45 970 21.6 
12 H CH2OH OH 41 420 10 
13 OH CH2N3 OH 770 n. i.c - 
14 OH CH2NH2 OH 393 110 0.3 
15 H (CH2)2OH OH 156 n. d. n. d. 
 
a Km-value 
bNo inhibition at 1000 M 
cNo inhibition at 4000 M 
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 FIGURE LEGENDS 
Figure 1. Schematic representation of the most important amino acid residues of TMPKmt 
interacting with dTMP (in black). The main bonding forces between dTMP and 
the enzyme are: (i) a stacking interaction between the pyrimidine ring and Phe70, 
(ii) a hydrogen bond between O4 of thymine and the Arg74 side-chain, which 
results in a preference for thymine over cytosine, (iii) a hydrogen bond between 
Asn100 and N3 of the thymine ring, (iv) a hydrogen bond between the 3’-hydroxyl 
of dTMP and the terminal carboxyl of Asp9, that in its turn interacts with the 
magnesium ion that is responsible for positioning the phosphate oxygen of dTMP, 
and (v) hydrogen bonds and an ionic interaction between the 5’-O-phosphoryl and 
Tyr39, Arg95 and Mg2+, respectively. The presence of Tyr103 close to the 2’-
position is believed to render the enzyme catalytically selective for 2’-deoxy 
nucleotides versus ribo nucleotides. 
 
Figure 2.  Predicted binding mode of 4 with TMPKmt. The sugar ring is in the 2’-exo-3’-
endo conformation and the 6'-amine lies at 2.64 Å of the carboxylic oxygen of 
Asp9. 
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9 R1= H, R2= N3
10 R1= H, R2= NH2
11 R1= H, R2= F
12 R1= H, R2= OH
13 R1= OH, R2= N3
14 R1= OH, R2= NH2
15 R1= H, R2= CH2OH 
3 R1= H, R2= N3
4 R1= H, R2= NH2
5 R1= H, R2= F
6 R1= H, R2= OH
7 R1= OH, R2= N3
8 R1= OH, R2= NH2
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Reagents: (a) BnCl, NaH, DMF. 
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Scheme 2 
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Reagents: (a) p-methoxyphenol, DEAD, Ph3P, THF. 
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Reagents: (a) p-methoxyphenol, DEAD, Ph3P, THF, 80 °C; (b) HOAc 75%, 80 °C; (c) Ac2O, pyridine; 
(d) 5-methyl-2,4-bis(trimethylsilyl)oxypyrimidine, (CH3)3SiOSO2CF3, Cl2(CH2)2; (e) NH3, MeOH; 
(f) phenylchlorothionocarbonate, DMAP, CH3CN; (g) AIBN, nBu3SnH, toluene. 
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Reagents: (a) H2, 10% Pd/C, MeOH; (b) POCl3, (MeO)3PO; (c) ceric ammonium nitrate, CH3CN, 
H2O; (d) DAST, CH2Cl2. 
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Reagents: (a) ceric ammonium nitrate, CH3CN, H2O; (b) methanesulfonyl chloride, pyridine; (c) 
NaN3, DMF, 95 °C; (d) BCl3, CH2Cl2, -78 °C; (e) POCl3, (MeO)3PO; (f) Ph3P, NH4OH, pyridine. 
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Reagents: (a) OsO4, 4-methylmorpholine N-oxide, dioxane; (b) NaIO4; (c) NaBH4, EtOH, 
H2O; (d) TBAF, THF.  
 
